ABSTRACT
Fundamento y objetivo: Comparar la rentabilidad de los índices PALIAR y PROFUND para predecir la mortalidad en pacientes pluripatológicos con enfermedad crónica no oncológica en fase avanzada. Material y métodos: Estudio de cohortes, prospectivo y multicéntrico con pacientes pluripatológicos con enfermedades crónicas no oncológicas en fase avanzada ingresados en departamentos de medicina interna entre el 1 de julio y el 31 de diciembre de 2014. Se recogieron datos de edad, género, categorías de pluripatología, enfermedad avanzada, comorbilidad, valoración funcional y cognitiva, síntomas de enfermedad terminal, necesidad de cuidador, ingresos en los 3 y 12 meses previos, número de fármacos, y se calcularon los índices PROFUND y PALIAR. Tras un seguimiento durante 12 meses la mortalidad se valoró con las curvas de supervivencia de Kaplan-Meier y la rentabilidad de los índices con las curvas ROC. Resultados: Se incluyeron 213 pacientes con edad media 83 (7) años y 106 (49,8%) eran mujeres. La mortalidad a los 6 meses fue del 40,4% y a los 12 del 50,2%. Los pacientes fallecidos puntuaban más alto en los índices PROFUND [11,2(4,2) frente a 8,5(3,9); p<0,001] y PALIAR [6,7 (4,6) frente a 3,6 (3,1); p<0,001]. La capacidad discriminativa del índice PALIAR a los 6 meses (área bajo la curva 0,734; IC95% 0,665-0,803) fue superior a la del índice PROFUND y no hubo diferencias a los 12 meses. Conclusiones: En pacientes pluripatológicos con enfermedad crónica en fase avanzada el índice PALIAR tiene un rendimiento mayor que el índice PROFUND para predecir la mortalidad a los 6 meses y similar a los 12 meses
Background and objective: To compare the discrimination power of PROFUND and PALIAR indexes for predicting mortality in polypathological patients with advanced non-oncologic chronic disease. Material and methods: Prospective multicentre cohort study. We included polypathological patients with advanced non-oncologic chronic disease, who were admitted to internal medicine departments between July 1st and December 31th, 2014. Data was collected from each patient on age, sex, categories of polypathology, advanced disease, comorbidity, functional and cognitive assessment, terminal illness symptoms, need for caregiver, hospitalisation in the past three and 12 months and number of drugs. We calculated the PROFUND and PALIAR indexes and conducted a 12-month follow-up. We assessed mortality with the Kaplan-Meier survival curves and the discrimination of indexes with the ROC curves. Results: We included 213 patients with a mean (standard deviation) age of 83.0 (7.0) years, 106 (49.8%) of whom were female. Mortality at six months was 40.4% and at 12 months 50.2%. Deceased patients scored higher scores on the PROFUND [11.2(4.2) vs 8.5(3.9); P<.001] and PALIAR [6.7 (4.6) vs 3.6(3.1); p<0,001] indexes. The discrimination of PALIAR index at six months (under the curve area 0.734 95%CI 0.665-0.803) was higher than of PROFUND, and there was no difference at 12 months. Conclusions: In polypathological patients with advanced non-oncologic chronic disease, the PALIAR index had better discrimination power than PROFUND index at 66 months and there were no differences at 12 months
Subject(s)
Humans , Aged, 80 and over , Chronic Disease , Terminal Care , Health Status Indicators , Cohort Studies , Prospective Studies , ROC Curve , Kaplan-Meier Estimate , Cognitive Dysfunction/diagnosis , Repertory, BarthelABSTRACT
BACKGROUND AND OBJECTIVE: To compare the discrimination power of PROFUND and PALIAR indexes for predicting mortality in polypathological patients with advanced non-oncologic chronic disease. MATERIAL AND METHODS: Prospective multicentre cohort study. We included polypathological patients with advanced non-oncologic chronic disease, who were admitted to internal medicine departments between July 1st and December 31th, 2014. Data was collected from each patient on age, sex, categories of polypathology, advanced disease, comorbidity, functional and cognitive assessment, terminal illness symptoms, need for caregiver, hospitalisation in the past three and 12 months and number of drugs. We calculated the PROFUND and PALIAR indexes and conducted a 12-month follow-up. We assessed mortality with the Kaplan-Meier survival curves and the discrimination of indexes with the ROC curves. RESULTS: We included 213 patients with a mean (standard deviation) age of 83.0 (7.0) years, 106 (49.8%) of whom were female. Mortality at six months was 40.4% and at 12 months 50.2%. Deceased patients scored higher scores on the PROFUND [11.2(4.2) vs 8.5(3.9); P<.001] and PALIAR [6.7 (4.6) vs 3.6(3.1); p<0,001] indexes. The discrimination of PALIAR index at six months (under the curve area 0.734 95%CI 0.665-0.803) was higher than of PROFUND, and there was no difference at 12 months. CONCLUSIONS: In polypathological patients with advanced non-oncologic chronic disease, the PALIAR index had better discrimination power than PROFUND index at 66 months and there were no differences at 12 months.
Subject(s)
Chronic Disease , Severity of Illness Index , Aged , Aged, 80 and over , Chronic Disease/mortality , Comorbidity , Diagnosis-Related Groups , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Polypharmacy , Prognosis , ROC Curve , Symptom AssessmentABSTRACT
Objetivo: Determinar la validez del índice PROFUND para establecer el riesgo de muerte global a los 4 años en pacientes pluripatológicos. Pacientes y métodos: Estudio de cohortes (Medicina Interna y Geriatría) prospectivo y multicéntrico. Se incluyeron pacientes pluripatológicos ingresados entre el 1 de marzo y el 30 de junio de 2011. Se recogieron datos de edad, sexo, si vivían en el domicilio o en una residencia, categorías de pluripatología, índices de Charlson, Lawton-Brody y Barthel, cuestionario de Pfeiffer, escala sociofamiliar de Gijón, delirium, número de fármacos, hemoglobina, creatinina e índice PROFUND. Se realizó un seguimiento durante 4 años. Resultados: Se incluyeron 441 pacientes, 324 de Medicina Interna y 117 de Geriatría, con una edad media de 80,9 (8,7) años, y 245 (55,6%) eran mujeres. Las enfermedades cardiacas (62,7%), neurológicas (41,4%) y respiratorias (37,3%) fueron las más frecuentes. Los pacientes de Geriatría eran de más edad, más dependientes y con más deterioro cognitivo. Al cabo de 4 años habían fallecido 335 (76%) pacientes. Los factores asociados de forma independiente con la mortalidad fueron la edad, la disnea, el índice de Barthel<60, el delirium, las neoplasias avanzadas y haber ingresado 4 o más veces en el último año. El rendimiento del índice PROFUND fue bueno en los pacientes de Medicina Interna y malo en los de Geriatría (0,748, IC 95% 0,689-0,806, p<0,001, y 0,517, IC 95% 0,369-0,666, p=0,818, respectivamente). Conclusiones: El índice PROFUND es útil para predecir la mortalidad global a largo plazo en los pacientes pluripatológicos de Medicina Interna, pero no en los de Geriatría (AU)
Objective: To determine the usefullness of the PROFUND index to assess the risk of global death after 4 years in polypathological patients. Patients and methods: Multicenter prospective cohort (Internal Medicine and Geriatrics) study. Polypathological patients admitted between March 1st and June 30th 2011 were included. For each patient, data concerning age, sex, living at home or in a nursing residence, polypathology categories, Charlson, Barthel and Lawton-Brody indexes, Pfeiffer questionnaire, socio-familial Gijon scale,delirium, number of drugs, hemoglobin and creatinine values were gathered, and the PROFUND index was calculated. The follow-up lasted 4 years. Results: We included 441 patients, 324 from Internal Medicine and 117 from Geriatrics, with a mean age of 80.9 (8.7) years. Of them, 245 (55.6%) were women. Heart (62.7%), neurological (41.4%) and respiratory (37.3%) diseases were the most frequent. Geriatrics inpatients were older and more dependants and presented greater cognitive deterioration. After 4 years, 335 (76%) patients died. Mortality was associated with age, dyspnoea, Barthel index<60,delirium, advanced neoplasia and≥4 admissions in the last year. The area under the curve of the PROFUND index was 0.748, 95% CI 0.689-0.806, P<.001 in Internal Medicine and 0.517, 95% CI 0.369-0.666, P=.818 in Geriatrics patients, respectively. Conclusions: The PROFUND index is a reliable tool for predicting long-term global mortality in polypathological patients from Internal Medicine but not from Geriatrics departments (AU)
Subject(s)
Humans , Male , Aged, 80 and over , Adult , Aged , Female , Middle Aged , Mortality , Comorbidity , Severity of Illness Index , ROC Curve , Prognosis , Prospective Studies , Spain/epidemiology , Follow-Up Studies , Geriatrics , Hospitalization , Internal Medicine , Risk AssessmentABSTRACT
OBJECTIVE: To determine the usefullness of the PROFUND index to assess the risk of global death after 4 years in polypathological patients. PATIENTS AND METHODS: Multicenter prospective cohort (Internal Medicine and Geriatrics) study. Polypathological patients admitted between March 1st and June 30th 2011 were included. For each patient, data concerning age, sex, living at home or in a nursing residence, polypathology categories, Charlson, Barthel and Lawton-Brody indexes, Pfeiffer questionnaire, socio-familial Gijon scale, delirium, number of drugs, hemoglobin and creatinine values were gathered, and the PROFUND index was calculated. The follow-up lasted 4 years. RESULTS: We included 441 patients, 324 from Internal Medicine and 117 from Geriatrics, with a mean age of 80.9 (8.7) years. Of them, 245 (55.6%) were women. Heart (62.7%), neurological (41.4%) and respiratory (37.3%) diseases were the most frequent. Geriatrics inpatients were older and more dependants and presented greater cognitive deterioration. After 4 years, 335 (76%) patients died. Mortality was associated with age, dyspnoea, Barthel index<60, delirium, advanced neoplasia and≥4 admissions in the last year. The area under the curve of the PROFUND index was 0.748, 95% CI 0.689-0.806, P<.001 in Internal Medicine and 0.517, 95% CI 0.369-0.666, P=.818 in Geriatrics patients, respectively. CONCLUSIONS: The PROFUND index is a reliable tool for predicting long-term global mortality in polypathological patients from Internal Medicine but not from Geriatrics departments.
